A Phase 3 program of bepirovirsen in chronic hepatitis B reported a functional cure signal after fixed-duration therapy. In two replicate randomized trials (B-Well 1 and B-Well 2), the proportion achieving functional cure at week 72 was 20% and 19% with bepirovirsen versus none in placebo groups. The analysis includes safety comparisons showing higher rates of adverse events and grade 3-or-higher liver enzyme elevations in the active arms. The readout is funded by GSK and published at NEJM.org, positioning bepirovirsen among the most advanced investigational efforts targeting HBV RNA for treatment discontinuation strategies.